HIV Infection: Clinical Trials

60 trials for HIV Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

60 completed. 60 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 460Completed 60

Follow HIV Infection: new trials by email Literature Review of HIV Infection trials Research Report on HIV Infection

Trials (filtered) newest first · largest first

All 60 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MAPS PrEP Van Study
Pre-Exposure Prophylaxis (PrEP) - HIV Infection
Phase 4CompletedDuke University72025-09-172026-07-24
Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial
Recombinant Human Papillomavirus Nonavalent Vaccine - HIV Infection
Phase 4CompletedFred Hutchinson Cancer Center972022-03-102026-07-02
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Dihydroartemisinin-piperaquine - Drug-Drug Interaction, HIV Infection
Phase 4CompletedUniversity of California, San Francisco1942020-11-232025-03-14
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
Estradiol Vaginal Insert - HIV Infection, Vaginal Atrophy
Phase 4CompletedKerry Murphy602020-09-012025-03-14
Nevirapine / Lamivudine for HIV Maintenance Therapy
Neviparine (NVP)/ Lamivudine (3TC) - HIV Infection, Antiretroviral Treatment
Phase 4CompletedCantonal Hospital of St. Gallen2012019-04-122025-06-10
Linking Infectious and Narcology Care-Part II
Rapid ART initiation, Pharmacotherapy for opioid use disorder, Strengths-based HIV case management - HIV Infection, Drug Use
Phase 4CompletedBoston Medical Center2252018-09-192023-04-18
Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Treatment simplification - HIV Infection
Phase 4CompletedUniversity of British Columbia102014-10-012017-11-06
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Sofosbuvir, Ribavirin, and Stribild - Hepatitis C Infection, HIV Infection
Phase 4CompletedSaint Michael's Medical Center102014-07-012016-08-04
Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject
Darunavir/Ritonavir, Lamivudine, Emtricitabine/tenofovir or abacavir/lamivudine - HIV Infection
Phase 4CompletedFundacion SEIMC-GESIDA2492014-07-012017-02-14
Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection
Raltegravir, Efavirenz - HCV Coinfection, HIV Infection
Phase 4CompletedJuan MacĂ­as452014-02-032017-07-25
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Raltegravir, Efavirenz - Hepatitis C, Chronic, HIV Infection
Phase 4CompletedUniversity of Hawaii802014-02-012021-08-13
Partners Demonstration Project of PrEP and ART
FTC-TDF PrEP, ART - HIV Infection
Phase 4CompletedUniversity of Washington10132012-11-012017-12-08
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Tenofovir, Emtricitabine, Lopinavir/r, Tenofovir, Emtricitabine, Raltegravir - HIV Infection
Phase 4CompletedHospital Clinic of Barcelona2402012-07-012015-04-01
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
Raltegravir switch - HIV Infection, Adverse Drug Reaction
Phase 4CompletedLin, Hsi-Hsun, M.D.1072012-07-012016-09-15
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
Tenofovir, emtricitabine, maraviroc, Tenofovir, emtricitabine, lopinavir/r - HIV Infection
Phase 4CompletedHospital Clinic of Barcelona2402012-02-012015-04-01
Early Antiviral Therapy for Critically Ill HIV Infected Patients
early HAART, Late HAART - HIV Infection
Phase 4CompletedHospital Nossa Senhora da Conceicao1152012-01-012018-04-12
Atazanavir/Ritonavir and Zinc Pharmacokinetic Study
1 Solvazinc tablet, day 2 to day 15, 1 Solvazinc tablet, day 15 to day 28 - HIV Infection
Phase 4CompletedSt Stephens Aids Trust162011-12-012012-03-22
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Atripla (r), Efavirenz, Truvada - HIV Infection
Phase 4CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections8512011-10-012024-10-15
Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression
antiretroviral treatment - HIV Infection
Phase 4CompletedJuan A. Arnaiz2502011-10-012014-07-29
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Ritonavir boosted Atazanavir + Lamivudine, Ritonavir boosted Atazanavir + 2 NRTIs - HIV Infection
Phase 4CompletedFundacion SEIMC-GESIDA2862011-09-012015-05-12

Showing 20 of 60. Sign in to see all of them.

Narrower conditions

HIV Infections (60)  ·  Acquired Immunodeficiency Syndrome (4)  ·  Hepatitis C (3)  ·  Cardiovascular Diseases (2)  ·  Dyslipidemias (2)  ·  Hepatitis B (2)  ·  Hepatitis C, Chronic (2)  ·  Infections (2)  ·  Lipodystrophy (2)  ·  Tuberculosis (2)  ·  Aging, Premature (1)  ·  Atrophic Vaginitis (1)  ·  Cognition Disorders (1)  ·  Coronary Disease (1)  ·  Diabetes Mellitus, Type 2 (1)

Broader conditions

Blood-Borne Infections (60)  ·  Communicable Diseases (60)  ·  Genital Diseases (60)  ·  Immune System Diseases (60)  ·  Immunologic Deficiency Syndromes (60)  ·  Lentivirus Infections (60)  ·  RNA Virus Infections (60)  ·  Retroviridae Infections (60)  ·  Sexually Transmitted Diseases (60)  ·  Sexually Transmitted Diseases, Viral (60)  ·  Urogenital Diseases (60)  ·  Virus Diseases (60)  ·  Infections (58)  ·  Digestive System Diseases (6)  ·  Hepatitis (6)

Interventions

Tenofovir (7)  ·  efavirenz (7)  ·  Emtricitabine (6)  ·  Lamivudine (6)  ·  Raltegravir Potassium (6)  ·  Ritonavir (6)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (5)  ·  Lopinavir (4)  ·  abacavir, lamivudine drug combination (4)  ·  lopinavir-ritonavir drug combination (4)  ·  Antiretroviral Therapy, Highly Active (3)  ·  Maraviroc (3)  ·  Omacor (3)  ·  abacavir (3)  ·  abacavir, lamivudine, and zidovudine drug combination (3)

Sponsors

GlaxoSmithKline (5)  ·  Fundacion SEIMC-GESIDA (4)  ·  University of California, San Francisco (3)  ·  University of Washington (3)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2)  ·  Hospital Clinic of Barcelona (2)  ·  Pfizer (2)  ·  Sociedad Andaluza de Enfermedades Infecciosas (2)  ·  St Stephens Aids Trust (2)  ·  Tufts University (2)  ·  University of British Columbia (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Arribas, Jose R., M.D. (1)  ·  Boston Medical Center (1)  ·  Cantonal Hospital of St. Gallen (1)

Countries

United States (26)  ·  Spain (15)  ·  Brazil (8)  ·  Switzerland (6)  ·  Uganda (6)  ·  Canada (5)  ·  Peru (5)  ·  Puerto Rico (5)  ·  United Kingdom (5)  ·  Haiti (4)  ·  Kenya (4)  ·  South Africa (4)  ·  Thailand (4)  ·  Australia (3)  ·  Austria (3)

Top investigators

Christine A Wanke, MD (2)  ·  Federico Pulido, MD (2)  ·  Felipe Garcia, PhD (2)  ·  Abdel Babiker, PhD (1)  ·  Adeodata Kekitiinwa (1)  ·  Ana Puga, MD (1)  ·  Ann Duerr, MD, PhD (1)  ·  Anna Wald, MD, MPH (1)  ·  Barbara Moscicki, MD (1)  ·  Carleen Townsend-Akpan, CPNP (1)  ·  Carlos R Rivera-Vazquez, MD (1)  ·  Cecilia M Shikuma, M.D. (1)

Results publications

PMID 18097218, PMID 18256392, PMID 18697216, PMID 19349870, PMID 19358725, PMID 19542866, PMID 19581631, PMID 21350366, PMID 21384334, PMID 21419775, PMID 21422117, PMID 21951596, PMID 21998479, PMID 22010914, PMID 22228003, PMID 22405335, PMID 22848378, PMID 22918156, PMID 23277897, PMID 23362296, PMID 23386261, PMID 23589670, PMID 24988179, PMID 25582793, PMID 25711317, PMID 25711318, PMID 25711319, PMID 25711320, PMID 25711321, PMID 25711322, PMID 25711323, PMID 25711324, PMID 25711325, PMID 25711326, PMID 25711327, PMID 25711328, PMID 25711329, PMID 25711330, PMID 25711331, PMID 25711332, PMID 26062880, PMID 26062881, PMID 26192873, PMID 26908541, PMID 26994089, PMID 26994091, PMID 27025337, PMID 28063815, PMID 28067119, PMID 28358734

NIH funding

2008 (3), U01AI068636 (2), 2014 (1), 2019 (1), K23AG062400 (1), K23DK079789 (1), P30AI064518 (1), R01DA013806 (1), R01DA045547 (1), R01HD068174 (1), R01HL096585 (1), R01MH095507 (1), U01AI068632 (1), U01AI068641 (1), U54CA242977 (1)